Chuvash polycythemia is a rare congenital form of polycythemia caused by homozygous R200W and H191D mutations in the VHL (von Hippel-Lindau) gene, whose gene product is the principal negative regulator of hypoxia-inducible factor. However, the molecular mechanisms underlying some of the hallmark abnormalities of Chuvash polycythemia, such as hypersensitivity to erythropoietin, are unclear. Here we show that VHL directly binds suppressor of cytokine signaling 1 (SOCS1) to form a heterodimeric E3 ligase that targets phosphorylated JAK2 (pJAK2) for ubiquitin-mediated destruction. In contrast, Chuvash polycythemia-associated VHL mutants have altered affinity for SOCS1 and do not engage with and degrade pJAK2. Systemic administration of a highly selective JAK2 inhibitor, TG101209, reversed the disease phenotype in Vhl R200W/R200W knock-in mice, an experimental model that recapitulates human Chuvash polycythemia. These results show that VHL is a SOCS1-cooperative negative regulator of JAK2 and provide biochemical and preclinical support for JAK2-targeted therapy in individuals with Chuvash polycythemia.
VHL protein is the substrate-conferring component of the E3 ubiquitin ligase complex ECV, composed of elongins B and C, Cul2 and VHL, which polyubiquitinates α subunits of hypoxia-inducible factor (HIF), a master transcription factor that governs adaptive cellular responses to hypoxia for oxygen-dependent destruction [1] [2] [3] [4] . Under hypoxic conditions, HIF-α escapes ECV-mediated destruction and partners with HIF-β to form an active transcription factor that engages with hypoxia-responsive elements in the promoters or enhancers of many hypoxia-inducible genes including SLC2A1 (glucose transporter-1, also known as GLUT-1), VEGFA (vascular endothelial growth factor) and EPO (erythropoietin) to promote anaerobic metabolism, angiogenesis and erythropoiesis, respectively 5 .
Inheritance of a mutated VHL gene causes VHL disease, an autosomal-dominant cancer syndrome characterized by the development of cerebellar and retinal hemangioblastoma, pheochromocytoma and clear-cell renal cell carcinoma (CCRCC) 5 . Although the incidence of VHL disease is rare, at one in 36,000 individuals, biallelic inactivation of VHL is frequently associated with sporadic hemangioblastoma and CCRCC 6 . Most tumor-associated VHL mutants have been shown or are predicted to compromise the ability of VHL to either bind prolyl-hydroxylated HIF-α or form a normal ECV complex 7, 8 , and additional studies have demonstrated the key oncogenic role of HIF-α in CCRCC [9] [10] [11] [12] . Recently, a specific homozygous mutation, C598T (resulting in the amino acid substitution R200W), was identified within VHL that causes congenital autosomal recessive Chuvash polycythemia endemic to the Chuvash Autonomous Republic of the Russian Federation 13 . Subsequently, R200W and additional mutations (for example, H191D) have been identified in a substantial proportion of subjects with congenital polycythemia in diverse ethnic backgrounds without gender bias [14] [15] [16] [17] , suggesting that a defect in the ability of these Chuvash polycythemia-associated VHL (CP-VHL) mutant proteins to maintain proper oxygen homeostasis is the principal mechanism underlying Chuvash polycythemia 13, 16, 18, 19 . Notably, unlike classical VHL disease, Chuvash polycythemia is not associated with an increased risk of cancer despite a common defect in the HIF pathway, and biochemical features distinguishing CP-VHL mutants from tumorassociated VHL mutants are currently unclear.
Polycythemia, characterized by a net increase in the total number of red blood cells (RBCs) leading to an elevated hematocrit, is generally categorized as primary or secondary. Primary polycythemia, often called polycythemia vera, is defined as excessive erythrocytosis arising from an intrinsic defect in erythroid progenitors rendering them hypersensitive to or independent of erythropoietin stimulation 20 . Secondary polycythemia is defined as excessive erythrocytosis arising from increased production of erythropoietin 20 , most often resulting from conditions of chronic hypoxia, such as in individuals with chronic obstructive pulmonary disease or smokers, but can also arise from paraneoplastic syndromes associated with certain malignancies including renal cell and hepatocellular carcinoma. Secondary polycythemia can also originate through mutations in PHD2 and HIF-2α that ultimately promote erythropoietin production [21] [22] [23] , as has been recapitulated in mice with constitutive expression of HIF-2α (refs. 16,24) .
JAK2 mutations, predominantly V617F, which results in constitutively active JAK2, have recently been identified in the vast majority of individuals with polycythemia vera [25] [26] [27] [28] [29] . JAK2 activation occurs downstream of erythropoietin stimulation, and JAK2 binds most prominently to the STAT5 protein, which, upon phosphorylation by JAK2, dimerizes and translocates to the nucleus to regulate expression of genes that control proliferation, differentiation and survival of hematopoietic cells 30 . STAT5 also triggers a negative feedback mechanism by transactivating the expression of SOCS family members, which bind and inhibit activated JAKs 31 . Notably, SOCS1 directly binds and targets phosphorylated JAK2 for ubiquitin-mediated degradation via the E3 ubiquitin ligase ECS complex (comprising elongins B and C, Cul2 or Cul5 and SOCS1) 32, 33 . Colony-forming unit-erythroid (CFU-E) cells from the fetal livers of Socs1 −/− mice are hyperresponsive to erythropoietin 34 Moreover, expression of the JAK2 V617F protein induces a polycythemia vera phenotype in mouse bone marrow transplantation assays, and introduction of JAK2 V617F into cytokinedependent cell lines promotes cytokine-independent signaling [35] [36] [37] [38] Regardless of JAK2 V617F mutation status, however, high STAT5 phosphorylation is detected in bone marrow biopsies of individuals with polycythemia vera 39 . These lines of evidence suggest that constitutive activation of JAK2-STAT5 signaling is a major causative determinant of polycythemia vera and that individuals with JAK2 V617F-negative polycythemia vera might harbor unidentified mutations in genes encoding proteins in the JAK2-STAT5 pathway.
Most people with Chuvash polycythemia, as well as Vhl R200W/R200W (Vhl R/R ) mice that recapitulate the human Chuvash polycythemia condition, have elevated erythropoietin concentrations in the blood, a hallmark of secondary polycythemia. This is consistent with the diminished capacity of VHL R200W to bind HIF-α (ref. 13 ), leading to increased HIF-mediated transactivation of. Notably, data from both mouse and human studies suggest that CP-VHL mutations mediate primary polycythemia. In particular, erythroid precursors from both individuals with Chuvash polycythemia and Vhl R/R mice have an intrinsic hypersensitivity to erythropoietin, as assessed by an increase in the number of burst forming unit-erythroid cells 13, 18 . However, the molecular mechanism underlying this and other primary polycythemic features of Chuvash polycythemia is unknown.
RESULTS

CP-VHL mutants have reduced capacity to form ECV
A subset of tumor-associated VHL mutants cannot form a normal ECV complex 12 . We first investigated whether CP-VHL mutants are similarly defective in binding to ECV components, and observed that CP-VHL mutants (including R200W and H191D, which show slightly faster electrophoretic migration relative to wild-type (WT) VHL under reducing conditions) have diminished association with elongins BC and Cul2 (Fig. 1a,b and Supplementary Fig. 1a) . The tumor-associated VHL C162F mutant, which is defective in forming an ECV complex 40 , served as a control. Thus, in addition to the previously reported defect in HIF-α binding 13 , CP-VHL mutants are compromised in ECV assembly, which also probably contributes to HIF-α stabilization.
All tumor-associated VHL mutants tested so far do not bind fibronectin and have a concomitant defect in formation of fibronectin fibrillar array in the extracellular space 41 . However, cells expressing CP-VHL mutants bound to fibronectin and promoted the formation of an extracellular fibrillar array with a distinct appearance similar to that observed using WT VHL ( Supplementary Fig. 1b and data not shown). Thus, VHL R200W and VHL H191D are, to our knowledge, the first disease-associated VHL mutants promoting normal fibronectin matrix deposition.
VHL binds JAK2 in a proteasome-and EPO-dependent manner In addition to reduced Cul2 binding, 35 S metabolic labeling of human CCRCC 786-O (defective in VHL expression) cells stably expressing VHL R200W or VHL H191D showed an associated 120-kDa protein, JAK2, in the absence of proteasome inhibitor (Fig. 1b) . Through its actions on STAT5 signaling, JAK2 is a key mediator of proliferation and survival of erythroid progenitor cells. Thus, we investigated whether VHL interacts with JAK2. Hemagglutinin-tagged WT VHL (WT HA-VHL) coprecipitated in a proteasome-dependent manner with T7-tagged JAK2 (T7-JAK2) when concurrently expressed in HEK293 cells (Fig. 1c) . Notably, in the absence of proteasome inhibitor, HA-VHL R200W or HA-VHL H191D showed greater association with pJAK2 than did WT HA-VHL (Fig. 1d) . These results identify JAK2 as a proteasome-sensitive VHL-binding substrate and suggest that CP-VHL mutants have a diminished capacity to promote proteasome-dependent degradation of JAK2. Notably, the total amount of JAK2 remained relatively unchanged upon WT HA-VHL expression (Fig. 1c,d) . We therefore sought to determine whether VHL bound and degraded pJAK2. Introduction of WT HA-VHL in HEK293 cells led to a marked loss of pJAK2, whereas total JAK2 expression remained relatively unchanged (Fig. 2a) . In addition, we stably infected a mouse hematopoietic cell line expressing erythropoietin receptor (BaF3-EPOR) with retrovirus encoding HA-tagged human VHL to generate cells with expression of HA-VHL at close to endogenous levels (Fig. 2b , compare endogenous mouse VHL (mVHL) to slower-migrating HA-human VHL). HA-VHL in BaF3-EPOR cells bound endogenous JAK2 preferentially upon erythropoietin stimulation in the presence of the proteasome inhibitor MG132, suggesting that the proteasome-sensitive substrate of VHL is pJAK2 (Fig. 2b) .
VHL promotes ubiquitin-mediated degradation of pJAK2
We next investigated whether VHL promotes ubiquitin-mediated degradation of activated JAK2, which is marked by phosphorylation of Tyr1007 or Tyr1008 (ref. 42) . We transfected HEK293 cells with plasmids encoding T7-JAK2 and EPOR and stimulated with erythropoietin for 15 min to generate high amounts of pJAK2 (Fig. 2c) . We then immunoprecipitated the whole-cell extract with antibodies to T7, and subjected the enriched T7-pJAK2 to an in vitro ubiquitination reaction using proteasome-depleted S100 cellular extracts generated from 786-O (VHL −/− ) cells ectopically expressing empty plasmid or WT VHL (Fig. 2c) . Although total JAK2 expression was unaffected, pJAK2 expression was markedly lower when WT VHL was added, accompanied by the appearance of pJAK2 polyubiquitination (Fig. 2c) . The low level of VHL-dependent ubiquitination observed without erythropoietin treatment is probably due to limited spontaneous JAK2 autophosphorylation, which is commonly observed upon ectopic JAK2 expression (Fig. 2c) . In addition, retrovirus-driven shRNA-mediated knockdown of endogenous mouse VHL in BaF3-EPOR cells led to increased pJAK2 levels and greater expression of downstream STAT5-responsive genes such as PIM1 and CISH upon erythropoietin treatment, as compared to BaF3-EPOR cells infected with retrovirus encoding nontargeting scrambled shRNA (Fig. 2d) . VHL knockdown had negligible effects on SOCS1 expression, indicating that nonspecific changes in SOCS1 expression probably do not explain the observed pJAK2 induction (Fig. 2d) . These results suggest that VHL preferentially engages with JAK2 upon EPOR activation to trigger ubiquitin-mediated downregulation of pJAK2.
Individuals with VHL disease rarely develop polycythemia despite harboring VHL mutations that compromise HIF-α degradation 18 . If deregulation of pJAK2 is involved in VHL-associated polycythemia, we would predict that tumor-associated VHL mutants that cannot bind or ubiquitinate HIF-α would retain the ability to promote ubiquitin-mediated destruction of pJAK2. Consistent with this prediction, expression of a panel of tumor-associated VHL mutants, with the exception of F119S and L128F (discussed below), led to markedly lower pJAK2 amounts in the absence MG132, similar to expression of WT VHL (Fig. 2e) . In addition, a panel of tumor-associated VHL mutants retained binding to JAK2 in the presence of MG132 (Supplementary Fig. 2) . Notably, expression of the well-established α domain VHL mutants C162F and L158S, which cannot form an ECV 40, 43 , likewise resulted in lower pJAK2 expression (Fig. 2e) . These results suggest that a previously unknown ECV-independent mechanism is responsible for VHL-mediated pJAK2 degradation. 10,000 100,000
Intensity To begin addressing whether the effects of VHL on HIF and JAK2 levels are independent of each other, we investigated the status of HIFand STAT5-responsive target genes in microarray data available for CCRCC and matched normal kidney samples 44 . The vast majority of CCRCCs harbor VHL-inactivating mutations, leading to HIF stabilization. We have previously shown that the gene expression changes induced by VHL inactivation are highly correlated with those induced by HIF activation 24 , and we therefore hypothesized that CCRCCs have high HIF-target gene expression. Relative to matched normal kidney, CCRCC samples expressed a classic hypoxic signature, including the upregulation of VEGFA and CA9 (encoding carbonic anhydrase IX) and downregulation of IGFBP2 (encoding insulin-like growth factor binding protein 2) (Fig. 2f) . In contrast, the STAT5-responsive genes SOCS1, CISH and RYK (encoding receptor-like tyrosine kinase) showed no discernible changes in RCC samples (Fig. 2f) , reinforcing the notion that the oncogenic defects that give rise to CCRCC probably do not involve JAK2 signaling.
VHL binds to and requires SOCS1 to promote pJAK2 degradation VHL and certain F-box proteins that confer substrate specificity have recently been shown to homodimerize [45] [46] [47] [48] [49] . Moreover, homodimerization of entire E3 enzymes such as the SCF complex (Skp1-Cdc53 or Cul1-F-box protein) increase the efficiency of ubiquitination by improving the spatial orientation between substrate and active site 49 . We investigated whether the F box-like protein SOCS1 interacts with VHL to promote ECV-independent degradation of pJAK2. When ectopically expressed in HEK293 cells, T7-VHL precipitated with HA-SOCS1, as shown by reciprocal co-immunoprecipitation experiments (Fig. 3a) . Coexpression of VHL with SOCS1, SOCS2 and SOCS3 showed preferential interaction between VHL and SOCS1 (Fig. 3b) , in keeping with the known role of SOCS1, but not of SOCS2 or SOCS3, in ubiquitin-mediated pJAK2 degradation 32, 50 . Notably, endogenous VHL precipitated with endogenous SOCS1 in BaF3-EPOR cells treated with erythropoietin (Fig. 3c) , and affinity-purified recombinant HA-VHL C162F, which cannot bind elongins B and C, Rbx1 and Cul2, bound specifically to renatured Flag-SOCS1 immobilized on membrane (Fig. 3d) . These results suggest that SOCS1 and VHL directly interact under physiological conditions. VHL F119S and VHL L128F mutants did not promote pJAK2 degradation (Figs. 3e and 2f) but could form an intact ECV to properly target HIF-α for degradation (Fig. 3f) , further supporting the notion that the defect in pJAK2 regulation is independent of ECV function. However, both F119S and L128F mutants were severely compromised in their ability to bind SOCS1 (Fig. 3g) despite retaining the ability to bind pJAK2 (data not shown), underscoring the requirement of binding to SOCS1, rather than formation of ECV complex, in VHL-mediated pJAK2 degradation. Analogous to the α domain of VHL, the SOCS box of SOCS1 facilitates recruitment of the ECS components Cul5, elongins BC and Rbx1 (refs. 33,51,52). Whereas both WT VHL and VHL C162F (an α domain mutant that cannot form an ECV) promoted pJAK2 degradation when coexpressed with WT SOCS1, coexpression of a SOCS1 mutant lacking the SOCS box (SOCS1∆SOCS-box) abrogated pJAK2 degradation (Fig. 3h) . These results suggest that the SOCS box is necessary for enzymatic activity of the VHL-SOCS1 heterocomplex for inducing the degradation of pJAK2.
CP-VHL has altered affinity for SOCS1
We next investigated whether the observed defect in pJAK2 degradation via CP-VHL was due to a failure in binding SOCS1. Unexpectedly, we found that both VHL R200W and VHL H191D mutants showed a marked increase in SOCS1 binding in comparison to WT VHL (Fig. 4a) , suggesting that mutations causing Chuvash polycythemia confer substantially higher affinity for SOCS1. We next investigated whether this altered affinity of CP-VHL mutants for SOCS1 affected pJAK2 recruitment. pJAK2 precipitated with substantially lower amounts of CP-VHL mutants in comparison to WT VHL, suggesting that the abnormal association between CP-VHL and SOCS1 hinders pJAK2 substrate binding (Fig. 4b) . We next directly compared the efficiency of WT VHL + SOCS1 versus CP-VHL + SOCS1 in promoting pJAK2 degradation. T7-pJAK2 was first generated by ectopic expression of EPOR and T7-JAK2 in HEK293 cells followed by erythropoietin stimulation. Cells were lysed and immunoprecipitated with antibody to T7. T7-pJAK2 enriched on beads were washed and equally distributed into four reaction tubes, as confirmed by comparable levels of T7-specific IgG light chain (Fig. 4c) , and mixed with HEK293 cell lysates expressing empty plasmid (mock) or HA-VHL (WT, R200W or H191D) in combination with HA-SOCS1. Lysate containing WT VHL + SOCS1 had a markedly reduced amount of pJAK2 in comparison to lysate containing CP-VHL + SOCS1 or SOCS1 only (Fig. 4c) . Consistent with this observation, erythropoietin-induced pJAK2 levels persisted longer in BaF3-EPOR-shVHL cells reconstituted with lentivirus-mediated HA-VHL R200W in comparison to reconstitution with WT HA-VHL (Fig. 4d) . These results indicate that the CP-VHL-SOCS1 heterocomplex is defective in promoting pJAK2 degradation. Size (AU) 
VHL negatively regulates EPOR-mediated colony growth
Stable knockdown of VHL in BaF3-EPOR cells increased the number of colonies in 1% vol/vol methylcellulose at subsaturating erythropoietin concentrations (Fig. 4e, 50 and 100 mU). In contrast, VHL knockdown did not significantly affect colony number in BaF3-EPOR cells at increasing IL-3 concentrations (Fig. 4e) , suggesting receptor specificity. We investigated whether the increased EPOR-specific colony formation upon VHL loss involved JAK2. We first found that the highly specific JAK2 inhibitor TG1012090 at concentration of 6 µM led to a mild reduction in colony formation of BaF3-EPOR cells plated on methylcellulose containing a subsaturating erythropoietin concentration (Supplementary Fig. 3 ). At this concentration of TG101209, the percentage inhibition of colony formation was more pronounced in BaF3-EPOR cells with stable VHL knockdown than in nontargeting control cells (Fig. 4f) . In addition to greater colony number, VHL loss led to larger colony size, which was reduced upon TG101209 treatment (Fig. 4g) . These results suggest that VHL negatively regulates EPOR-mediated colony growth and size in a JAK2-dependent manner.
JAK2 inhibitor treatment corrects CP phenotypes in vivo
Vhl R/R mice harboring a homozygous R200W mutation develop agedependent polycythemia with significant elevations in hematocrit starting at 14-16 weeks of age 18 . We generated a cohort of Vhl R/R mice (all mice were at least 20 weeks old) and treated them with TG101209 (100 mg per kg body weight) or vehicle by twice daily oral gavage 53 . The hematocrit of TG101209-treated Vhl R/R mice steadily declined from baseline, whereas the hematocrit of vehicle-treated Vhl R/R mice was relatively unchanged (mean hematocrit at 5 weeks of treatment, 35.4% and 49.4%, respectively, P < 0.05; Fig. 5a ). The hematocrit of TG101209-treated WT mice declined as expected (mean hematocrit decreased from ~42% to 33% over 5 weeks). The effect of TG101209 on hematocrits was also evident by inspection of the plantar footpads of treated versus untreated Vhl R/R mice but not of treated versus untreated WT mice ( Fig. 5b and Supplementary Fig. 4 ). Splenomegaly is a common distinguishing feature of primary polycythemia and is evident in Vhl R/R mice 18 . At the time of necropsy, the spleens of vehicle-treated Vhl R/R mice were larger than those of their TG101209-treated counterparts (Fig. 5c) . In contrast, the spleens of WT mice treated with TG101209 or vehicle were indistinguishable (Supplementary Fig. 4) . The spleens of Vhl R/R mice have more megakaryocytes than do WT mice, another feature of primary polycythemia not evident in secondary polycythemia 18 . We evaluated H&E-stained sections of spleens and found significantly more megakaryocytes in vehicle-treated Vhl R/R mice than in TG101209-treated mice (Fig. 5c,d , P < 0.005). These results suggest that splenomegaly and the greater proliferation of megakaryocytes in Vhl R/R mice are JAK2 dependent.
We next investigated to what extent our in vivo findings were mediated in a cell-autonomous manner. Erythroid progenitors from individuals with polycythemia vera are hypersensitive to erythropoietin owing to JAK2-activating mutations associated with greater amounts of phosphorylated JAK2 and STAT5 (ref. 39) . Consistent with earlier reports showing that erythroid progenitors from individuals with Chuvash polycythemia and from Vhl R/R mice are hypersensitive to erythropoietin 13, 18 , we observed more CFU-E colonies in erythropoietin-treated erythroid progenitors from Vhl R/R mice than from WT mice (Fig. 5e) . To determine whether this hypersensitivity was mediated in a JAK2-dependent manner, we first investigated whether pJAK2 was upregulated in the erythroid precursors of Vhl R/R mice. To this end, we generated singlecell suspensions enriched with erythroid progenitors from spleens of phenylhydrazine-treated Vhl R/R or WT mice, and then removed residual cytokines by washes in cytokine-free medium. We cytokine-starved the cells for an additional 4 h to purge any preexisting stimulation of the JAK2-STAT5 pathway and subsequently treated them with increasing concentrations of exogenous erythropoietin for 15 min. Amounts of pJAK2 and pSTAT5 were markedly higher in Vhl R/R compared to WT erythroid progenitor-enriched cell lysates (Fig. 5f) , suggesting that the hypersensitivity of Vhl R/R progenitors to erythropoietin might be mediated in a JAK2-dependent manner. Moreover, VHL R200W isolated from Vhl R/R splenic cells precipitated with endogenous SOCS1 and JAK2 (Fig. 5g) .
To further ascertain whether the hypersensitivity of Vhl R/R erythroid precursors to erythropoietin was mediated in a JAK2-dependent manner, we evaluated the effects of JAK2 inhibition by carrying out CFU-E assays using hematopoietic precursors isolated from the spleens of Vhl R/R mice that were cultured in the presence or absence of erythropoietin and in the presence of TG101309 or vehicle. No CFU-E colonies formed in the absence of erythropoietin using hematopoietic precursors treated with TG101209 or vehicle (data not shown). In the presence of erythropoietin, significantly fewer CFU-E colonies formed in hematopoietic precursors cultured with TG101209 relative to vehicle (Fig. 5h) , suggesting that the hypersensitivity of Vhl R/R hematopoietic precursors to erythropoietin is mediated in a JAK2 dependent-manner. These results indicate that homozygous R200W mutation increases JAK2-STAT5 signaling and imparts hypersensitivity to erythropoietin in a JAK2-dependent manner.
DISCUSSION
Mapping of VHL disease-associated mutations on the VHL-elongin B-elongin C (VBC) crystal structure engaged with HIF-1α peptide revealed two major VHL domains, α and β, that are required for elongin C and HIF-1α binding, respectively 7, 8, 54 . VHL mutations that disrupt (F119S and L128F) or enhance (R200W and H191D) SOCS1 binding are notably clustered in a unique third region of VHL, indicating a probable protein-protein interaction interface or 'SOCS groove' required for the engagement of SOCS1 (Fig. 6a) . Notably, the SOCS groove does not overlap with the elongin C-or HIF-1α-binding interface. This is consistent with the observed independence of HIFand JAK2-associated functions of VHL, as exemplified by F119S and L128F mutants, which can degrade HIF-α but not pJAK2 despite the ability of these mutants to form the ECV complex. Conversely, the α domain C162F mutant can degrade pJAK2 despite its inability to form the ECV complex and degrade HIF-α.
Our findings support the following revised model of Chuvash polycythemia (Fig. 6b) . In normal individuals, VHL forms a normal ECV complex and negatively regulates HIF-α via the ubiquitin pathway. In contrast, Chuvash polycythemia-associated mutations attenuate HIF-α binding and formation of the ECV complex, causing the reported mild stabilization of HIF-α, which leads to overproduction of the HIF-target erythropoietin in the kidney and thereby to secondary polycythemia. In normal individuals, VHL also binds SOCS1 through its SOCS groove and triggers ubiquitin-mediated pJAK2 degradation and thus negatively regulates the JAK2-STAT5 pathway. Chuvash polycythemia-associated mutations cause conformational changes within the SOCS groove, leading to a tight CP-VHL-SOCS1 association, thereby impeding pJAK2 recruitment and degradation. The resulting pJAK2 stabilization promotes hyperactivation of the JAK2-STAT5 pathway in erythroid progenitors, causing hypersensitivity to erythropoietin and thereby to primary polycythemia.
Polycythemia vera-associated JAK2 V617F mutation gives rise to not only uncontrolled expansion of RBCs but also pleomorphic and clustered megakaryocytes hypersensitive to thrombopoietin, which, similar to erythropoietin, signals through JAK2 via the thrombopoietin receptor 35 . Abnormal megakaryocyte function is thought to be a crucial factor contributing to thrombotic complications frequently observed in individuals with polycythemia vera 42 . Notably, Vhl R/R mice have more clustered megakaryocytes than do WT mice, and individuals with Chuvash polycythemia, like those with polycythemia vera, often present with thrombotic complications 13, 18 . In contrast, secondary polycythemia associated with elevated serum erythropoietin does not lead to megakaryocytic defects, consistent with the lack of thrombotic complications despite very high RBC count in mice with constitutive overexpression of erythropoietin 55 . Moreover, some individuals with Chuvash polycythemia do not appear to have elevated serum erythropoietin levels 15, 17, 56 . These observations suggest that hyperactive JAK2-STAT5 signaling, rather than increased erythropoietin production due to a mild defect in HIF regulation, is the principal mechanism underlying thrombotic complications in individuals with Chuvash polycythemia. Perhaps more important, the ability of pharmacologic JAK2 inhibition to normalize the number of splenic megakaryocytes in Vhl R/R mice suggests that JAK2 inhibition has the potential to not only lower the hematocrit of individuals with Chuvash polycythemia but also to lower the rate of thrombotic complications. The discovery of JAK2 mutations in humans with polycythemia vera has expedited clinical trials of JAK2 inhibitors in the management of polycythemia vera. However, despite clinical features shared between polycythemia vera and Chuvash polycythemia, including hypersensitivity to erythropoietin and megakaryocytic defects associated with thrombotic complications, JAK2 inhibitors have not to our knowledge been proposed as a therapy for individuals with Chuvash polycythemia, as the key role of JAK2 in the pathogenesis of Chuvash polycythemia has not been previously appreciated. Our findings not only indicate molecular cooperativity between VHL and SOCS1 in the negative regulation of the JAK2-STAT5 pathway but also provide biochemical and preclinical evidence for JAK2-targeted therapy in individuals with Chuvash polycythemia.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
